Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima
Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the prima
禮來公司和Incell公司宣佈了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究的結果,該試驗在初始階段沒有統計學意義
Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the primary endpoint'
Lilly And Incyte Announce Results From The Phase 3 COV-BARRIER Study Of Baricitinib In Hospitalized Covid-19 Patients' The Co,'s Report 'The trial did not meet statistical significance on the primary endpoint'
禮來公司和Incell公司公佈了巴利替尼在住院新冠肺炎患者中的3期COV屏障研究結果,該公司的報告稱,該試驗沒有達到主要終點的統計學意義。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!